A Phase 3 interventional study of Cladribine and Placebo in Multiple Sclerosis, sponsored by EMD Serono Research & Development Institute, Inc.. Completed at 158 sites in 34 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-03-22.
Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing cladribine in Multiple Sclerosis — 2 open to participants now, 5 under way, 2 of them phase 3. Cladribine · Multiple Sclerosis.
Among the 14 studies testing cladribine in Multiple Sclerosis, this one has the largest enrollment, is one of 2 that started in 2008, is one of 2 in phase 3, and was the 2nd registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.
Browse Multiple Sclerosis studies →2 of the 14 studies testing cladribine in Multiple Sclerosis are open now, in 2 countries. Recruiting first, the newest first:
Institute of Psychiatry and Neurology, Warsaw · Sites in Poland
Ages 30–65
Keith Edwards, M.D. · Sites in United States
Ages 21–65
By country, each count listing its studies:
Cladribine: first FDA approval 1993 (LEUSTATIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 4 · Phase 4 8
First in 2006; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 617 is above the median of 50 across 2,205 interventional studies indexed under Multiple Sclerosis.
Median enrollment 196 across the 14 interventional studies. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 14 have an industry lead sponsor. The 10 most frequent:
This study is registered under EMD Serono Research & Development Institute, Inc., one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono Research & Development Institute, Inc. is the lead sponsor of 87 studies on the registry; 8 are open to participants now.
Of its 47 completed or terminated interventional studies of FDA-regulated products, 38 (81%) have results posted.
71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany: none open now, 1 under way, none of them phase 3. Of 70 finished, 42 (60%) have results posted.
Among the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany, this one is the 4th largest by enrollment of the 33 interventional ones that give a count, is one of 13 that started in 2008, is one of 11 in phase 3, and was the 10th registered.
Merck KGaA, Darmstadt, Germany’s Multiple Sclerosis studies by the year they started, since 2000.
2 of the studies testing cladribine in Multiple Sclerosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05961644Phase 3Institute of Psychiatry and Neurology, WarsawCladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS). | 2027-06-30 |
| NCT04178005University of Texas Southwestern Medical CenterCladribine Tablets After Treatment With Natalizumab (CLADRINA) | 2027-05-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing cladribine in Multiple Sclerosis, from their registry updates:
Among Merck KGaA, Darmstadt, Germany’s 71 in Multiple Sclerosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A randomized, double-blind, clinical trial to assess the safety and efficacy of two doses of oral cladribine versus placebo in participants who had a first clinical demyelinating event (clinically isolated syndrome). Participants in either the cladribine or placebo group may also enter treatment periods with open-label interferon-beta or open-label cladribine depending upon the disease status. The primary objective of this study is to evaluate the effect of two dosage regimens of oral cladribine versus placebo on the time to conversion to multiple sclerosis (MS) (from randomization) according to the Poser criteria in participants with first clinical demyelinating event at high risk of converting to MS.
This will be a randomized, double blind, three-arm, placebo-controlled, multi-center trial to evaluate the safety and efficacy of oral cladribine versus placebo in the treatment of participants who have sustained a first clinical demyelinating event within 75 days prior to the Screening. Participants must have a minimum of 2 clinically silent lesions on the Screening magnetic resonance imaging (MRI).
The study will include a pre-study evaluation period (Screening period: between 10 and 28 days prior to the start of treatment with blinded study medication (oral cladribine or placebo).
Depending upon the clinical course of their MS, participants will then proceed from the ITP to either the Maintenance Treatment Period (with open-label interferon-beta treatment) or LTFU period (with either open-label low-dose cladribine or no additional treatment (if no progression to MS has been noted after the initial treatment period). The single primary endpoint for the overall study, which will be determined during the ITP, is time to conversion to MS (from randomization), according to the Poser criteria.
For every participants, eligibility for study enrollment and entry into each of the study periods, and diagnosis of conversion to either McDonald MS or CDMS must be confirmed and approved by a Sponsor appointed study Adjudication Committee.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If female, she must:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 milligrams per kilograms (mg/kg) during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.
Drug: Cladribine · Drug: Rebif® new formulation (RNF)
Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.
Drug: Cladribine · Drug: Rebif® new formulation (RNF)
Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.
Drug: Placebo · Drug: Rebif® new formulation (RNF)
Participants who received cladribine 5.25 mg/kg and converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received Rebif® new formulation (RNF) subcutaneously at a dose of 44 microgram (mcg) three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.
Drug: Cladribine · Drug: Rebif® new formulation (RNF)
Participants who received cladribine 3.5 mg/kg and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.
Drug: Cladribine · Drug: Rebif® new formulation (RNF)
Participants who received placebo and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.
Drug: Placebo
Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
Drug: Cladribine · Drug: Rebif® new formulation (RNF)
Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
Drug: Cladribine · Drug: Rebif® new formulation (RNF)
Participants who received placebo and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
Drug: Placebo
Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
Drug: Cladribine · Drug: Rebif® new formulation (RNF)
Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
Drug: Cladribine · Drug: Rebif® new formulation (RNF)
Participants who received placebo and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who convert to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
Drug: Placebo
Cladribine tablets were administered until CDMS conversion, whichever occur first.
Placebo matched to cladribine tablets were administered.
Participants who converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received RNF subcutaneously at a dose of 44 microgram (mcg) three times a week. Participants who converted to CDMS during long-term follow-up (LTFU) period, received RNF subcutaneously at a dose of 44 mcg three times a week.
ITP: Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS
CDMS according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to Multiple Sclerosis \[MS\]) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (\>=) 1 point if baseline EDSS was between \>= 1.0 and less than or equal to (=\<) 4.5; or \>= 1.5 points if baseline EDSS was 0, or \>= 0.5 if baseline EDSS \>= 5.0 over a period of at least 3 months. Kaplan-Meier estimates were provided for of the cumulative (cum.) percentage (%) of participants with CDMS over time. The probability of patients remaining event-free over time (from randomization) in each of the three treatment groups was displayed in the form of survival curves estimated using the non-parametric Kaplan-Meier method.
Time frame: ITP: Baseline up to Week 96
ITP: Time to Develop Multiple Sclerosis (MS) Conversion According to the Revised McDonald Criteria (2005) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With McDonald MS
The McDonald criteria use dissemination in time and space established by magnetic resonance imaging (MRI) findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new time constant 2 (T2) or gadolinium enhanced (Gd+) lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions. Kaplan-Meier estimates were provided for the cum. percentage (%) of participants with McDonald MS over time.
Time frame: ITP: Baseline up to Week 96
ITP: Number of Combined Unique Active (CUA) Lesions, New or Enlarging Time Constant 2 (T2) Lesions, and New or Persisting Time Constant 1 (T1) Gadolinium Enhanced (Gd+) Lesions Per Participant Per Scan
Number of CUA lesions, new or enlarging T2 lesions, and new or persisting T1 Gd+ lesions were measured by using magnetic resonance imaging (MRI) scans.
Time frame: ITP: Baseline up to Week 96
OLMP: Time to 3 Month Confirmed Expanded Disability Status Scale (EDSS) Progression From Randomization Represented by Kaplan-Meier Estimates of Probability of Disability Progression
EDSS progression is based on a standardized neurological exam and focuses on symptoms that commonly occur in Multiple Sclerosis (MS). Overall scores ranges from 0.0 (normal) to 10.0 (death due to MS). A sustained progression on EDSS score was defined as an EDSS progression confirmed into two consecutive assessment. Probability of disability progression at different time points was estimated using Kaplan-Meier method on the time to disability progression defined as the time from randomization to first EDSS increase.
Time frame: OLMP: Day 1, 90, 180, 270, 360, 450, 540, 630, 720 and 810
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Time to Conversion to Multiple Sclerosis (MS) According to the 2005 McDonald Criteria
The McDonald criteria use dissemination in time and space established by magnetic resonance imaging (MRI) findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new time constant 2 (T2) or gadolinium enhanced (Gd+) lesion found on a repeat MRI.
Time frame: Time from Randomization up to 1217 days
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) According to Poser Criteria
CDMS according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (\>=) 1 point if baseline EDSS was between \>= 1.0 and less than or equal to (=\<) 4.5; or \>= 1.5 points if baseline EDSS was 0, or \>= 0.5 if baseline EDSS \>= 5.0 over a period of at least 3 months.
Time frame: Time from Randomization up to 1217 days
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) According to Poser Criteria
CDMS according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (\>=) 1 point if baseline EDSS was between \>= 1.0 and less than or equal to (=\<) 4.5; or \>= 1.5 points if baseline EDSS was 0, or \>= 0.5 if baseline EDSS \>= 5.0 over a period of at least 3 months.
Time frame: Time from Randomization up to 1217 days
ITP: Percentage of Participants Converting to Clinically Definite Multiple Sclerosis (CDMS) as Per Poser Criteria
Clinically definite multiple sclerosis (CDMS) according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (\>=) 1 point if baseline EDSS was between \>= 1.0 and less than or equal to (=\<) 4.5; or \>= 1.5 points if baseline EDSS was 0, or \>= 0.5 if baseline EDSS \>= 5.0 over a period of at least 3 months. The percentage of participants who converted to CDMS are reported here.
Time frame: ITP: Baseline up to week 96
ITP: Percentage of Participants Converting to McDonald Multiple Sclerosis (MS) (2005)
Percentage of participants converting to mcDonald multiple sclerosis (2005) were reported.
Time frame: ITP: Baseline up to week 96
ITP: Number of New or Persisting Gd-enhanced Lesions
Number of new or persisting Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.
Time frame: ITP: Week 13, 24, 36, 48, 60, 72, 84 and 96
OLMP: Number of New or Persisting Gd-enhanced Lesions
Number of new or persisting Gd-Enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.
Time frame: OLMP: Baseline, Week 24, 48, 72 and 96
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of New or Persisting Gd-enhanced Lesions
Number of new or persisting Gd-Enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.
Time frame: LTFU: Baseline, Week 13, 24 and 36
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of New or Persisting Gd-enhanced Lesions
Number of new or persisting Gd-Enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.
Time frame: LTFU: Baseline, Week 13, 24, 36 and 48
ITP: Number of New or Enlarging T2 Lesions
Number of new or enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans.
Time frame: ITP: Week 13, 24, 36, 48, 60, 72, 84 and 96
OLMP: Number of New or Enlarging T2 Lesions
Number of new or enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans.
Time frame: OLMP: Baseline, Week 24, 48, 72 and 96
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of New or Enlarging T2 Lesions
Number of new or enlarging T2 Lesions were measured by using magnetic resonance imaging (MRI) scans.
Time frame: LTFU: Baseline, Week 13, 24 and 36
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of New or Enlarging T2 Lesions
Number of new or enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans.
Time frame: LTFU: Baseline, Week 13, 24, 36 and 48
ITP: Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions
Number of CUA lesions were measured by using magnetic resonance imaging (MRI) scans.
Time frame: ITP: Week 13, 24, 36, 48, 60, 72, 84 and 96
OLMP: Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions
Number of combined unique active (CUA) lesions were measured by using magnetic resonance imaging (MRI) scans.
Time frame: OLMP: Baseline, Week 24, 48, 72 and 96
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions
Number of CUA MRI lesions were measured by using magnetic resonance imaging (MRI) scans.
Time frame: LTFU: Baseline, Week 13, 24 and 36
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions
Number of CUA lesions were measured by using magnetic resonance imaging (MRI) scans.
Time frame: LTFU: Baseline, Week 13, 24, 36 and 48
ITP: Change From Baseline in Volume of T1 Gd-Enhanced Lesions
Change in volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.
Time frame: ITP: Baseline, Week 96
OLMP: Mean Volume of T1 Gd-Enhanced Lesions and Changes From Baseline in Volume of T1 Gd-Enhanced Lesions
Volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.
Time frame: OLMP: Baseline, Week 24, 48, 72 and 96
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Mean Volume of T1 Gd-Enhanced Lesions and Changes From Baseline in Volume of T1 Gd-Enhanced Lesions
Volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.
Time frame: LTFU: Baseline, Week 13, 24 and 36
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Mean Volume of T1 Gd-Enhanced Lesions and Changes From Baseline in Volume of T1 Gd-Enhanced Lesions
Volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.
Time frame: LTFU: Baseline, Week 13, 24, 36 and 48
ITP: Changes From Baseline in Volume of T2 Lesions
Change in volume of T2 lesions from baseline was measured by using magnetic resonance imaging (MRI) scans.
Time frame: ITP: Baseline, Week 48 and 96
OLMP: Mean Volume of T2 Lesions and Changes From Baseline in Volume of T2 Lesions
Volume of T2 lesions was measured by using magnetic resonance imaging (MRI) scans.
Time frame: OLMP: Baseline, Week 48 and 96
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Mean Volume of T2 Lesions
Volume of T2 lesions was measured by using magnetic resonance imaging (MRI) scans.
Time frame: LTFU: Baseline (Day 1)
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Mean Volume of T2 Lesions and Changes From Baseline in Volume of T2 Lesions
Volume of T2 lesions was measured by using magnetic resonance imaging (MRI) scans.
Time frame: Baseline, Week 48
ITP: Number of T1 Hypointense Lesions
Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.
Time frame: ITP: Baseline, Week 48 and 96
OLMP: Number of T1 Hypointense Lesions
Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.
Time frame: OLMP: Baseline, Week 48 and 96
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of T1 Hypointense Lesions
Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.
Time frame: LTFU: Baseline (Day 1)
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of T1 Hypointense Lesions
Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.
Time frame: LTFU: Baseline, Week 48
ITP: Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions
T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.
Time frame: ITP: Baseline up to Week 96
OLMP: Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions
T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.
Time frame: OLMP: Baseline up to Week 96
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions
T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.
Time frame: LTFU: Baseline up to Week 48
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions
T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.
Time frame: Baseline up to Week 48
ITP: Percentage of Participants With no New or Enlarging T2 Lesions
T2 lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or enlarging T2 lesions were reported.
Time frame: ITP: Baseline up to Week 96
OLMP: Percentage of Participants With no New or Enlarging T2 Lesions
T2 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or enlarging T2 Lesions were reported.
Time frame: OLMP: Baseline up to 96
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Percentage of Participants With no New or Enlarging T2 Lesions
Enlarging T2 Lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no New or Enlarging T2 Lesions were reported.
Time frame: Baseline up to Week 48
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Percentage of Participants With no New or Enlarging T2 Lesions
Enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no New or Enlarging T2 lesions were reported.
Time frame: LTFU: Baseline up to Week 48
ITP: Percent Change From Baseline in Brain Volume
Brain volume was measured by using magnetic resonance imaging (MRI) scans. Percent change from baseline in brain volume at Week 48 and 96 was reported.
Time frame: ITP: Baseline, Week 48 and 96
OLMP: Percent Change From Baseline in Brain Volume
Brain volume was measured by using magnetic resonance imaging (MRI) scans. Percent change from baseline in brain volume at Week 48 and 96 was reported.
Time frame: OLMP: Baseline, Week 48 and 96
OLMP: Number of Relapses
Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.
Time frame: Baseline up to Week 96
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of Relapses
Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.
Time frame: Baseline up to Week 48
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of Relapses
Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.
Time frame: Baseline up to Week 48
OLMP: Annualized Relapse Rate
The annualized relapse rate for each treatment group was the mean of the annualized relapse rates for all the participants in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25. Where, Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.
Time frame: Baseline up to Week 96
OLMP: Percentage of Relapse-Free Participants
Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days. Percentage of relapse-free participants were reported.
Time frame: Baseline up to Week 96
ITP: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious TEAEs and non-serious TEAEs. Number of Participants with TEAEs and serious TEAEs were reported.
Time frame: ITP: Baseline up to Week 96
A total of 617 participants were randomized for initial treatment period (ITP) and 616 participants received study drug.
| Milestone | Cladribine 5.25 mg/kg (ITP) | Cladribine 3.5 mg/kg (ITP) | Placebo (ITP) | Cladribine 5.25 mg/kg, Rebif (OLMP) | Cladribine 3.5 mg/kg, Rebif (OLMP) | Placebo, Rebif (OLMP) | Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU) | Cladribine 5.25 mg/kg, Rebif (LTFU) | Cladribine 3.5 mg/kg, Rebif (LTFU) | Placebo, Rebif (LTFU) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 205 | 206 | 206 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Treated | 204 | 206 | 206 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 104 | 131 | 104 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 101 | 75 | 102 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 20 | 10 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Randomized but not treated | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Converted to cdms | 30 | 27 | 71 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 50 | 38 | 24 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cladribine 5.25 mg/kg (ITP) | Cladribine 3.5 mg/kg (ITP) | Placebo (ITP) | Cladribine 5.25 mg/kg, Rebif (OLMP) | Cladribine 3.5 mg/kg, Rebif (OLMP) | Placebo, Rebif (OLMP) | Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU) | Cladribine 5.25 mg/kg, Rebif (LTFU) | Cladribine 3.5 mg/kg, Rebif (LTFU) | Placebo, Rebif (LTFU) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 24 | 25 | 60 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 6 | 2 | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 18 | 23 | 53 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 | 2 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Disease progression | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 15 | 20 | 44 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cladribine 5.25 mg/kg (ITP) | Cladribine 3.5 mg/kg (ITP) | Placebo (ITP) | Cladribine 5.25 mg/kg, Rebif (OLMP) | Cladribine 3.5 mg/kg, Rebif (OLMP) | Placebo, Rebif (OLMP) | Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU) | Cladribine 5.25 mg/kg, Rebif (LTFU) | Cladribine 3.5 mg/kg, Rebif (LTFU) | Placebo, Rebif (LTFU) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 9 | 17 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 9 | 17 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 8 | 16 | 0 | 0 | 0 |
| Milestone | Cladribine 5.25 mg/kg (ITP) | Cladribine 3.5 mg/kg (ITP) | Placebo (ITP) | Cladribine 5.25 mg/kg, Rebif (OLMP) | Cladribine 3.5 mg/kg, Rebif (OLMP) | Placebo, Rebif (OLMP) | Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU) | Cladribine 5.25 mg/kg, Rebif (LTFU) | Cladribine 3.5 mg/kg, Rebif (LTFU) | Placebo, Rebif (LTFU) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 34 | 36 | 14 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 34 | 36 | 14 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 34 | 36 | 14 |
CDMS according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to Multiple Sclerosis \[MS\]) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (\>=) 1 point if baseline EDSS was between \>= 1.0 and less than or equal to (=\<) 4.5; or \>= 1.5 points if baseline EDSS was 0, or \>= 0.5 if baseline EDSS \>= 5.0 over a period of at least 3 months. Kaplan-Meier estimates were provided for of the cumulative (cum.) percentage (%) of participants with CDMS over time. The probability of patients remaining event-free over time (from randomization) in each of the three treatment groups was displayed in the form of survival curves estimated using the non-parametric Kaplan-Meier method.
| Cum. % of participants with CDMS | Cladribine 5.25 mg/kg (ITP) | Cladribine 3.5 mg/kg (ITP) | Placebo (ITP) |
|---|---|---|---|
| ITP: Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS | 15.8 | 14.0 | 37.8 |
The McDonald criteria use dissemination in time and space established by magnetic resonance imaging (MRI) findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new time constant 2 (T2) or gadolinium enhanced (Gd+) lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions. Kaplan-Meier estimates were provided for the cum. percentage (%) of participants with McDonald MS over time.
| Cum. % of participants with McDonald MS | Cladribine 5.25 mg/kg (ITP) | Cladribine 3.5 mg/kg (ITP) | Placebo (ITP) |
|---|---|---|---|
| ITP: Time to Develop Multiple Sclerosis (MS) Conversion According to the Revised McDonald Criteria (2005) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With McDonald MS | 51.36 | 56.05 | 87.14 |
Number of CUA lesions, new or enlarging T2 lesions, and new or persisting T1 Gd+ lesions were measured by using magnetic resonance imaging (MRI) scans.
| Lesions | Cladribine 5.25 mg/kg (ITP) | Cladribine 3.5 mg/kg (ITP) | Placebo (ITP) |
|---|---|---|---|
| CUA lesions | 1.20 ± 5.79 | 0.65 ± 1.80 | 2.13 ± 2.87 |
| New or persisting T1 Gd+ lesions | 0.61 ± 5.33 | 0.29 ± 0.97 | 0.97 ± 1.62 |
| New or enlarging T2 lesions | 0.62 ± 1.90 | 0.40 ± 1.12 | 1.17 ± 1.87 |
EDSS progression is based on a standardized neurological exam and focuses on symptoms that commonly occur in Multiple Sclerosis (MS). Overall scores ranges from 0.0 (normal) to 10.0 (death due to MS). A sustained progression on EDSS score was defined as an EDSS progression confirmed into two consecutive assessment. Probability of disability progression at different time points was estimated using Kaplan-Meier method on the time to disability progression defined as the time from randomization to first EDSS increase.
| Probability of Disability Progression | Cladribine 5.25 mg/kg, Rebif (OLMP) | Cladribine 3.5 mg/kg, Rebif (OLMP) | Placebo, Rebif (OLMP) |
|---|---|---|---|
| Day 1 | 0.0000 (0.0000 to 0.0000) | 0.0000 (0.0000 to 0.0000) | 0.0000 (0.0000 to 0.0000) |
| Day 90 | 0.0000 (0.0000 to 0.0000) | 0.0000 (0.0000 to 0.0000) | 0.0000 (0.0000 to 0.0000) |
| Day 180 | 0.0417 (-0.0383 to 0.1216) | 0.0417 (-0.0383 to 0.1216) | 0.0527 (-0.0054 to 0.1108) |
| Day 270 | 0.0417 (-0.0383 to 0.1216) | 0.0417 (-0.0383 to 0.1216) | 0.0527 (-0.0054 to 0.1108) |
| Day 360 | 0.0417 (-0.0383 to 0.1216) | 0.0417 (-0.0383 to 0.1216) | 0.0527 (-0.0054 to 0.1108) |
| Day 450 | 0.0417 (-0.0383 to 0.1216) | 0.0417 (-0.0383 to 0.1216) | 0.0764 (0.0035 to 0.1492) |
| Day 540 | 0.0417 (-0.0383 to 0.1216) | 0.0417 (-0.0383 to 0.1216) | 0.1094 (0.0147 to 0.2041) |
| Day 630 | 0.0417 (-0.0383 to 0.1216) | 0.0417 (-0.0383 to 0.1216) | 0.1094 (0.0147 to 0.2041) |
| Day 720 | 0.0417 (-0.0383 to 0.1216) | 0.0417 (-0.0383 to 0.1216) | 0.1094 (0.0147 to 0.2041) |
The McDonald criteria use dissemination in time and space established by magnetic resonance imaging (MRI) findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new time constant 2 (T2) or gadolinium enhanced (Gd+) lesion found on a repeat MRI.
| Days | Cladribine 5.25 mg/kg, Rebif (LTFU) | Cladribine 3.5 mg/kg, Rebif (LTFU) | Placebo, Rebif (LTFU) |
|---|---|---|---|
| LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Time to Conversion to Multiple Sclerosis (MS) According to the 2005 McDonald Criteria | 773 | — | — |
CDMS according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (\>=) 1 point if baseline EDSS was between \>= 1.0 and less than or equal to (=\<) 4.5; or \>= 1.5 points if baseline EDSS was 0, or \>= 0.5 if baseline EDSS \>= 5.0 over a period of at least 3 months.
| Days | Cladribine 5.25 mg/kg, Rebif (LTFU) | Cladribine 3.5 mg/kg, Rebif (LTFU) | Placebo, Rebif (LTFU) |
|---|---|---|---|
| LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) According to Poser Criteria | 773 | — | — |
CDMS according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (\>=) 1 point if baseline EDSS was between \>= 1.0 and less than or equal to (=\<) 4.5; or \>= 1.5 points if baseline EDSS was 0, or \>= 0.5 if baseline EDSS \>= 5.0 over a period of at least 3 months.
| Days | Cladribine 5.25 mg/kg, Rebif (LTFU) | Cladribine 3.5 mg/kg, Rebif (LTFU) | Placebo, Rebif (LTFU) |
|---|---|---|---|
| LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) According to Poser Criteria | — | — | 767 |
Clinically definite multiple sclerosis (CDMS) according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (\>=) 1 point if baseline EDSS was between \>= 1.0 and less than or equal to (=\<) 4.5; or \>= 1.5 points if baseline EDSS was 0, or \>= 0.5 if baseline EDSS \>= 5.0 over a period of at least 3 months. The percentage of participants who converted to CDMS are reported here.
| Percentage of participants | Cladribine 5.25 mg/kg (ITP) | Cladribine 3.5 mg/kg (ITP) | Placebo (ITP) |
|---|---|---|---|
| ITP: Percentage of Participants Converting to Clinically Definite Multiple Sclerosis (CDMS) as Per Poser Criteria | 28.8 | 23.1 | 56.3 |
Percentage of participants converting to mcDonald multiple sclerosis (2005) were reported.
| Percentage of participants | Cladribine 5.25 mg/kg (ITP) | Cladribine 3.5 mg/kg (ITP) | Placebo (ITP) |
|---|---|---|---|
| ITP: Percentage of Participants Converting to McDonald Multiple Sclerosis (MS) (2005) | 70.7 | 71.6 | 91.8 |
Number of new or persisting Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.
| Lesions | Cladribine 5.25 mg/kg (ITP) | Cladribine 3.5 mg/kg (ITP) | Placebo (ITP) |
|---|---|---|---|
| Week 13 | 0.86 ± 5.60 | 0.37 ± 1.52 | 1.00 ± 1.98 |
| Week 24 | 0.03 ± 0.20 | 0.13 ± 0.51 | 0.92 ± 1.69 |
| Week 36 | 0.08 ± 0.38 | 0.14 ± 0.44 | 0.74 ± 1.28 |
| Week 48 | 0.02 ± 0.13 | 0.27 ± 0.92 | 0.87 ± 1.81 |
| Week 60 | 0.10 ± 0.84 | 0.22 ± 0.94 | 0.74 ± 1.61 |
| Week 72 | 0.05 ± 0.53 | 0.16 ± 0.81 | 0.90 ± 1.88 |
| Week 84 | 0.02 ± 0.13 | 0.32 ± 2.62 | 0.60 ± 1.20 |
| Week 96 | 0.07 ± 0.43 | 0.18 ± 0.84 | 0.64 ± 1.25 |
Number of new or persisting Gd-Enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.
| Lesions | Cladribine 5.25 mg/kg, Rebif (OLMP) | Cladribine 3.5 mg/kg, Rebif (OLMP) | Placebo, Rebif (OLMP) |
|---|---|---|---|
| Baseline | 1.38 ± 5.52 | 0.88 ± 1.80 | 1.27 ± 2.58 |
| Week 24 | 0.17 ± 0.48 | 0.05 ± 0.21 | 0.11 ± 0.56 |
| Week 48 | 0.07 ± 0.24 | 0.00 ± 0.00 | 0.20 ± 0.50 |
| Week 72 | 1.50 ± 3.28 | 0.13 ± 0.35 | 0.33 ± 1.18 |
| Week 96 | 1.58 ± 2.69 | 0.00 ± 0.00 | 0.07 ± 0.26 |
Number of new or persisting Gd-Enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.
| Lesions | Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU) |
|---|---|---|---|
| Baseline | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.71 ± 1.16 |
| Week 13 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.13 ± 0.34 |
| Week 24 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.18 ± 0.40 |
| Week 36 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 |
Number of new or persisting Gd-Enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.
| Lesions | Cladribine 5.25 mg/kg, Rebif (LTFU) | Cladribine 3.5 mg/kg, Rebif (LTFU) | Placebo, Rebif (LTFU) |
|---|---|---|---|
| Baseline | 0.00 ± 0.00 | 0.06 ± 0.23 | 0.14 ± 0.36 |
| Week 13 | 0.00 ± 0.00 | 0.07 ± 0.23 | 0.09 ± 0.30 |
| Week 24 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.20 ± 0.45 |
| Week 36 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.17 ± 0.29 |
| Week 48 | 0.00 | — | — |
Number of new or enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans.
| Lesions | Cladribine 5.25 mg/kg (ITP) | Cladribine 3.5 mg/kg (ITP) | Placebo (ITP) |
|---|---|---|---|
| Week 13 | 1.56 ± 3.52 | 1.25 ± 3.33 | 1.43 ± 2.56 |
| Week 24 | 0.24 ± 0.95 | 0.20 ± 0.66 | 1.01 ± 1.70 |
| Week 36 | 0.09 ± 0.40 | 0.12 ± 0.42 | 1.14 ± 1.87 |
| Week 48 | 0.07 ± 0.50 | 0.32 ± 2.52 | 1.04 ± 1.54 |
| Week 60 | 0.13 ± 0.63 | 0.25 ± 1.09 | 0.71 ± 1.57 |
| Week 72 | 0.03 ± 0.22 | 0.10 ± 0.34 | 0.83 ± 1.77 |
| Week 84 | 0.09 ± 0.46 | 0.28 ± 2.03 | 0.61 ± 1.31 |
| Week 96 | 0.04 ± 0.25 | 0.10 ± 0.59 | 0.38 ± 0.85 |
Number of new or enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans.
| Lesions | Cladribine 5.25 mg/kg, Rebif (OLMP) | Cladribine 3.5 mg/kg, Rebif (OLMP) | Placebo, Rebif (OLMP) |
|---|---|---|---|
| Baseline | 0.29 ± 0.75 | 1.54 ± 6.72 | 2.13 ± 7.29 |
| Week 24 | 0.26 ± 0.69 | 0.43 ± 1.35 | 0.68 ± 1.10 |
| Week 48 | 0.32 ± 0.65 | 0.38 ± 1.09 | 0.41 ± 0.71 |
| Week 72 | 0.95 ± 1.85 | 0.25 ± 0.46 | 0.97 ± 1.69 |
| Week 96 | 2.00 ± 3.52 | 0.67 ± 1.15 | 0.47 ± 1.06 |
Number of new or enlarging T2 Lesions were measured by using magnetic resonance imaging (MRI) scans.
| Lesions | Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU) |
|---|---|---|---|
| Baseline | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.71 ± 1.53 |
| Week 13 | 0.00 ± 0.00 | 0.25 ± 0.46 | 2.06 ± 4.25 |
| Week 24 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Week 36 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.10 ± 0.32 |
Number of new or enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans.
| Lesions | Cladribine 5.25 mg/kg, Rebif (LTFU) | Cladribine 3.5 mg/kg, Rebif (LTFU) | Placebo, Rebif (LTFU) |
|---|---|---|---|
| Baseline | 0.00 ± 0.00 | 0.03 ± 0.17 | 0.07 ± 0.27 |
| Week 13 | 0.00 ± 0.00 | 0.04 ± 0.21 | 0.18 ± 0.40 |
| Week 24 | 0.00 ± 0.00 | 0.13 ± 0.35 | 0.00 ± 0.00 |
| Week 36 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.33 ± 0.58 |
| Week 48 | 0.00 | — | — |
Number of CUA lesions were measured by using magnetic resonance imaging (MRI) scans.
| Lesions | Cladribine 5.25 mg/kg (ITP) | Cladribine 3.5 mg/kg (ITP) | Placebo (ITP) |
|---|---|---|---|
| Week 13 | 2.37 ± 6.87 | 1.56 ± 4.04 | 2.41 ± 3.89 |
| Week 24 | 0.26 ± 1.03 | 0.29 ± 0.89 | 1.91 ± 2.93 |
| Week 36 | 0.16 ± 0.71 | 0.25 ± 0.70 | 1.84 ± 2.64 |
| Week 48 | 0.09 ± 0.59 | 0.56 ± 3.05 | 1.89 ± 2.78 |
| Week 60 | 0.23 ± 1.40 | 0.42 ± 1.87 | 1.44 ± 2.70 |
| Week 72 | 0.08 ± 0.72 | 0.22 ± 1.03 | 1.66 ± 3.05 |
| Week 84 | 0.11 ± 0.51 | 0.55 ± 4.52 | 1.14 ± 1.95 |
| Week 96 | 0.11 ± 0.60 | 0.23 ± 1.39 | 0.99 ± 1.89 |
Number of combined unique active (CUA) lesions were measured by using magnetic resonance imaging (MRI) scans.
| Lesions | Cladribine 5.25 mg/kg, Rebif (OLMP) | Cladribine 3.5 mg/kg, Rebif (OLMP) | Placebo, Rebif (OLMP) |
|---|---|---|---|
| Baseline | 0.63 ± 1.17 | 2.17 ± 7.72 | 3.23 ± 8.07 |
| Week 24 | 0.42 ± 1.02 | 0.48 ± 1.40 | 0.79 ± 1.33 |
| Week 48 | 0.39 ± 0.81 | 0.38 ± 1.09 | 0.61 ± 1.02 |
| Week 72 | 2.45 ± 5.01 | 0.38 ± 0.74 | 1.30 ± 2.71 |
| Week 96 | 3.33 ± 6.03 | 0.67 ± 1.15 | 0.53 ± 1.25 |
Number of CUA MRI lesions were measured by using magnetic resonance imaging (MRI) scans.
| Lesions | Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU) |
|---|---|---|---|
| Baseline | 0.00 ± 0.00 | 0.00 ± 0.00 | 1.24 ± 2.49 |
| Week 13 | 0.00 ± 0.00 | 0.00 ± 0.00 | 2.19 ± 4.46 |
| Week 24 | 0.00 ± 0.00 | 0.25 ± 0.46 | 0.18 ± 0.40 |
| Week 36 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.10 ± 0.32 |
Number of CUA lesions were measured by using magnetic resonance imaging (MRI) scans.
| Lesions | Cladribine 5.25 mg/kg, Rebif (LTFU) | Cladribine 3.5 mg/kg, Rebif (LTFU) | Placebo, Rebif (LTFU) |
|---|---|---|---|
| Baseline | 0.00 ± 0.00 | 0.03 ± 0.17 | 0.14 ± 0.36 |
| Week 13 | 0.00 ± 0.00 | 0.04 ± 0.21 | 0.18 ± 0.40 |
| Week 24 | 0.00 ± 0.00 | 0.13 ± 0.35 | 0.00 ± 0.00 |
| Week 36 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.33 ± 0.58 |
| Week 48 | 0.00 | — | — |
Change in volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.
| cubic millimeters (mm^3) | Cladribine 5.25 mg/kg (ITP) | Cladribine 3.5 mg/kg (ITP) | Placebo (ITP) |
|---|---|---|---|
| ITP: Change From Baseline in Volume of T1 Gd-Enhanced Lesions | -73.97 ± 204.80 | -126.64 ± 399.39 | 48.63 ± 239.03 |
Volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.
| mm^3 | Cladribine 5.25 mg/kg, Rebif (OLMP) | Cladribine 3.5 mg/kg, Rebif (OLMP) | Placebo, Rebif (OLMP) |
|---|---|---|---|
| Baseline | 91.06 ± 368.98 | 113.64 ± 248.74 | 136.61 ± 344.31 |
| Week 24 | 7.71 ± 26.35 | 3.48 ± 16.70 | 9.14 ± 55.62 |
| Week 48 | 5.22 ± 19.75 | 0.00 ± 0.00 | 39.00 ± 188.80 |
| Week 72 | 219.52 ± 377.85 | 56.86 ± 160.83 | 25.85 ± 96.18 |
| Week 96 | 330.20 ± 442.02 | 0.00 ± 0.00 | 22.51 ± 87.17 |
| Change at Week 24 | -87.30 ± 379.50 | -120.04 ± 250.42 | -134.67 ± 343.19 |
| Change at Week 48 | -106.82 ± 415.70 | -146.62 ± 298.86 | -116.06 ± 429.90 |
| Change at Week 72 | 26.00 ± 600.82 | -155.91 ± 341.97 | -192.24 ± 439.11 |
| Change at Week 96 | 275.83 ± 360.07 | -391.93 ± 523.92 | -247.76 ± 593.34 |
Volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.
| mm^3 | Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU) |
|---|---|---|---|
| Baseline | 0.00 ± 0.00 | 0.00 ± 0.00 | 79.43 ± 143.64 |
| Week 13 | 0.00 ± 0.00 | 0.00 ± 0.00 | 20.56 ± 70.96 |
| Week 24 | 0.00 ± 0.00 | 0.00 ± 0.00 | 25.23 ± 66.24 |
| Week 36 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Change at Week 13 | 0.00 ± 0.00 | 0.00 ± 0.00 | -63.83 ± 147.43 |
| Change at Week 24 | 0.00 ± 0.00 | 0.00 ± 0.00 | -32.25 ± 113.96 |
| Change at Week 36 | 0.00 ± 0.00 | 0.00 ± 0.00 | -58.93 ± 85.19 |
Volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.
| mm^3 | Cladribine 5.25 mg/kg, Rebif (LTFU) | Cladribine 3.5 mg/kg, Rebif (LTFU) | Placebo, Rebif (LTFU) |
|---|---|---|---|
| Baseline | 0.00 ± 0.00 | 4.45 ± 21.25 | 27.79 ± 76.02 |
| Week 13 | 0.00 ± 0.00 | 7.34 ± 27.76 | 17.43 ± 57.80 |
| Week 24 | 0.00 ± 0.00 | 0.00 ± 0.00 | 57.22 ± 127.95 |
| Week 36 | 0.00 ± 0.00 | 0.00 ± 0.00 | 57.22 ± 99.10 |
| Week 48 | 0.00 | — | — |
| Change at Week 13 | 0.00 ± 0.00 | 0.38 ± 1.32 | -17.95 ± 41.38 |
| Change at Week 24 | 0.00 ± 0.00 | -2.48 ± 9.60 | -20.60 ± 57.89 |
| Change at Week 36 | 0.00 ± 0.00 | -5.31 ± 14.06 | -31.48 ± 54.53 |
| Change at Week 48 | 0.00 | — | — |
Change in volume of T2 lesions from baseline was measured by using magnetic resonance imaging (MRI) scans.
| mm^3 | Cladribine 5.25 mg/kg (ITP) | Cladribine 3.5 mg/kg (ITP) | Placebo (ITP) |
|---|---|---|---|
| Baseline | 3825.73 ± 5093.52 | 3435.22 ± 5184.12 | 3436.69 ± 4613.43 |
| Change at Week 48 | -654.20 ± 2061.85 | -828.97 ± 3513.04 | -29.57 ± 2581.44 |
| Change at Week 96 | -1237.44 ± 2718.76 | -1605.63 ± 2889.61 | -886.39 ± 2955.44 |
Volume of T2 lesions was measured by using magnetic resonance imaging (MRI) scans.
| mm^3 | Cladribine 5.25 mg/kg, Rebif (OLMP) | Cladribine 3.5 mg/kg, Rebif (OLMP) | Placebo, Rebif (OLMP) |
|---|---|---|---|
| Baseline | 398.88 ± 1102.27 | 630.70 ± 1707.24 | 1019.30 ± 2872.03 |
| Week 48 | 767.66 ± 1875.86 | 458.13 ± 984.12 | 508.97 ± 1159.97 |
| Week 96 | 2606.15 ± 5542.81 | 0.00 ± 0.00 | 647.17 ± 1345.62 |
| Change at Week 48 | 523.27 ± 2065.54 | -20.20 ± 2025.21 | -77.67 ± 1760.20 |
| Change at Week 96 | 2245.18 ± 5810.53 | 0.00 ± 0.00 | 255.39 ± 1352.80 |
Volume of T2 lesions was measured by using magnetic resonance imaging (MRI) scans.
| mm^3 | Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU) |
|---|---|---|---|
| LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Mean Volume of T2 Lesions | 1217.53 ± 1991.21 | 587.79 ± 1491.20 | 702.30 ± 1254.66 |
Volume of T2 lesions was measured by using magnetic resonance imaging (MRI) scans.
| mm^3 | Cladribine 5.25 mg/kg, Rebif (LTFU) | Cladribine 3.5 mg/kg, Rebif (LTFU) | Placebo, Rebif (LTFU) |
|---|---|---|---|
| Baseline | 1402.08 ± 1799.96 | 962.26 ± 1026.99 | 1407.75 ± 1890.94 |
| Week 48 | 0.00 | — | — |
| Change at Week 48 | -969.90 | — | — |
Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.
| Lesions | Cladribine 5.25 mg/kg (ITP) | Cladribine 3.5 mg/kg (ITP) | Placebo (ITP) |
|---|---|---|---|
| Baseline | 8.0 ± 11.7 | 7.3 ± 12.2 | 7.0 ± 8.6 |
| Week 48 | 8.39 ± 12.60 | 6.95 ± 12.86 | 7.07 ± 8.75 |
| Week 96 | 5.35 ± 8.14 | 3.82 ± 6.89 | 5.06 ± 6.82 |
Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.
| Lesions | Cladribine 5.25 mg/kg, Rebif (OLMP) | Cladribine 3.5 mg/kg, Rebif (OLMP) | Placebo, Rebif (OLMP) |
|---|---|---|---|
| Baseline | 0.92 ± 2.22 | 2.32 ± 9.52 | 1.45 ± 3.53 |
| Week 48 | 3.79 ± 8.32 | 1.00 ± 2.85 | 0.74 ± 1.83 |
| Week 96 | 0.50 ± 0.84 | 0.00 ± 0.00 | 1.47 ± 2.80 |
Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.
| Lesions | Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU) |
|---|---|---|---|
| LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of T1 Hypointense Lesions | 4.44 ± 7.25 | 1.22 ± 3.31 | 2.24 ± 5.01 |
Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.
| Lesions | Cladribine 5.25 mg/kg, Rebif (LTFU) | Cladribine 3.5 mg/kg, Rebif (LTFU) | Placebo, Rebif (LTFU) |
|---|---|---|---|
| Baseline | 5.74 ± 8.21 | 3.53 ± 5.78 | 2.93 ± 4.46 |
| Week 48 | 4.50 | — | — |
T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.
| Percentage of Participants | Cladribine 5.25 mg/kg (ITP) | Cladribine 3.5 mg/kg (ITP) | Placebo (ITP) |
|---|---|---|---|
| ITP: Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions | 67.0 | 57.1 | 21.6 |
T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.
| Percentage of participants | Cladribine 5.25 mg/kg, Rebif (OLMP) | Cladribine 3.5 mg/kg, Rebif (OLMP) | Placebo, Rebif (OLMP) |
|---|---|---|---|
| OLMP: Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions | 25.0 | 50.0 | 35.3 |
T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.
| Percentage of Participants | Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU) |
|---|---|---|---|
| LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions | 0 | 0 | 0 |
T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.
| Percentage of participants | Cladribine 5.25 mg/kg, Rebif (LTFU) | Cladribine 3.5 mg/kg, Rebif (LTFU) | Placebo, Rebif (LTFU) |
|---|---|---|---|
| LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions | 0 | 0 | 0 |
T2 lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or enlarging T2 lesions were reported.
| Percentage of Participants | Cladribine 5.25 mg/kg (ITP) | Cladribine 3.5 mg/kg (ITP) | Placebo (ITP) |
|---|---|---|---|
| ITP: Percentage of Participants With no New or Enlarging T2 Lesions | 32.9 | 35.1 | 19.0 |
T2 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or enlarging T2 Lesions were reported.
| Percentage of participants | Cladribine 5.25 mg/kg, Rebif (OLMP) | Cladribine 3.5 mg/kg, Rebif (OLMP) | Placebo, Rebif (OLMP) |
|---|---|---|---|
| OLMP: Percentage of Participants With no New or Enlarging T2 Lesions | 18.2 | 16.7 | 13.5 |
Enlarging T2 Lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no New or Enlarging T2 Lesions were reported.
| Percentage of Participants | Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU) |
|---|---|---|---|
| LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Percentage of Participants With no New or Enlarging T2 Lesions | 0 | 0 | 0 |
Enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no New or Enlarging T2 lesions were reported.
| Percentage of participants | Cladribine 5.25 mg/kg, Rebif (LTFU) | Cladribine 3.5 mg/kg, Rebif (LTFU) | Placebo, Rebif (LTFU) |
|---|---|---|---|
| LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Percentage of Participants With no New or Enlarging T2 Lesions | 0 | 0 | 0 |
Brain volume was measured by using magnetic resonance imaging (MRI) scans. Percent change from baseline in brain volume at Week 48 and 96 was reported.
| Percent change | Cladribine 5.25 mg/kg (ITP) | Cladribine 3.5 mg/kg (ITP) | Placebo (ITP) |
|---|---|---|---|
| Week 48 | -0.47 ± 0.63 | -0.48 ± 0.69 | -0.33 ± 0.76 |
| Week 96 | -0.59 ± 0.80 | -0.72 ± 0.73 | -0.75 ± 0.65 |
Brain volume was measured by using magnetic resonance imaging (MRI) scans. Percent change from baseline in brain volume at Week 48 and 96 was reported.
| Percent change | Cladribine 5.25 mg/kg, Rebif (OLMP) | Cladribine 3.5 mg/kg, Rebif (OLMP) | Placebo, Rebif (OLMP) |
|---|---|---|---|
| Week 48 | -0.41 ± 0.98 | -1.60 ± 1.40 | -0.56 ± 1.11 |
| Week 96 | 0.06 ± 1.36 | — | -1.31 ± 0.76 |
Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.
| Relapses | Cladribine 5.25 mg/kg (ITP) | Cladribine 3.5 mg/kg (ITP) | Placebo (ITP) |
|---|---|---|---|
| OLMP: Number of Relapses | 0.33 ± 0.64 | 0.16 ± 0.37 | 0.55 ± 1.00 |
Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.
| Relapses | Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU) |
|---|---|---|---|
| LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of Relapses | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.06 ± 0.24 |
Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.
| Relapses | Cladribine 5.25 mg/kg, Rebif (LTFU) | Cladribine 3.5 mg/kg, Rebif (LTFU) | Placebo, Rebif (LTFU) |
|---|---|---|---|
| LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of Relapses | 0.03 ± 0.17 | 0.03 ± 0.17 | 0.00 ± 0.00 |
The annualized relapse rate for each treatment group was the mean of the annualized relapse rates for all the participants in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25. Where, Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.
| relapses per year | Cladribine 5.25 mg/kg (ITP) | Cladribine 3.5 mg/kg (ITP) | Placebo (ITP) |
|---|---|---|---|
| OLMP: Annualized Relapse Rate | 0.24 (0.07 to 0.40) | 0.14 (0.00 to 0.27) | 0.42 (0.28 to 0.56) |
Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days. Percentage of relapse-free participants were reported.
| Percentage of participants | Cladribine 5.25 mg/kg (ITP) | Cladribine 3.5 mg/kg (ITP) | Placebo (ITP) |
|---|---|---|---|
| OLMP: Percentage of Relapse-Free Participants | 40.0 | 20.0 | 30.8 |
An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious TEAEs and non-serious TEAEs. Number of Participants with TEAEs and serious TEAEs were reported.
| Participants | Cladribine 5.25 mg/kg (ITP) | Cladribine 3.5 mg/kg (ITP) | Placebo (ITP) |
|---|---|---|---|
| TEAEs | 165 | 168 | 162 |
| Serious TEAEs | 12 | 23 | 22 |
Collected over ITP: Baseline up to 96 weeks; OLMP: Baseline up to 96 weeks; LTFU: Baseline up to 48 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cladribine 5.25 mg/kg (ITP) | 0/204 (0%) | 12/204 (5.9%) | 133/204 (65.2%) |
| Cladribine 3.5 mg/kg (ITP) | 0/206 (0%) | 23/206 (11.2%) | 132/206 (64.1%) |
| Placebo (ITP) | 0/206 (0%) | 22/206 (10.7%) | 116/206 (56.3%) |
| Cladribine 5.25 mg/kg, Rebif (OLMP) | 0/24 (0%) | 1/24 (4.2%) | 18/24 (75%) |
| Cladribine 3.5 mg/kg, Rebif (OLMP) | 1/25 (4%) | 4/25 (16%) | 19/25 (76%) |
| Placebo, Rebif (OLMP) | 0/60 (0%) | 5/60 (8.3%) | 41/60 (68.3%) |
| Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | 0/9 (0%) | 0/9 (0%) | 3/9 (33.3%) |
| Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | 0/9 (0%) | 0/9 (0%) | 4/9 (44.4%) |
| Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU) | 0/16 (0%) | 1/16 (6.3%) | 7/16 (43.8%) |
| Cladribine 5.25 mg/kg, Rebif (LTFU) | 0/34 (0%) | 0/34 (0%) | 2/34 (5.9%) |
| Cladribine 3.5 mg/kg, Rebif (LTFU) | 0/36 (0%) | 1/36 (2.8%) | 0/36 (0%) |
| Placebo, Rebif (LTFU) | 0/14 (0%) | 0/14 (0%) | 2/14 (14.3%) |
| Event | Cladribine 5.25 mg/kg (ITP) | Cladribine 3.5 mg/kg (ITP) | Placebo (ITP) | Cladribine 5.25 mg/kg, Rebif (OLMP) | Cladribine 3.5 mg/kg, Rebif (OLMP) | Placebo, Rebif (OLMP) | Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU) | Cladribine 5.25 mg/kg, Rebif (LTFU) | Cladribine 3.5 mg/kg, Rebif (LTFU) | Placebo, Rebif (LTFU) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood creatine phosphokinase increasedInvestigations | 3/204 | 7/206 | 4/206 | 1/24 | 0/25 | 0/60 | 0/9 | 0/9 | 1/16 | 0/34 | 0/36 | 0/14 |
| Cardio-respiratory arrestCardiac disorders | 0/204 | 0/206 | 0/206 | 0/24 | 1/25 | 0/60 | 0/9 | 0/9 | 0/16 | 0/34 | 0/36 | 0/14 |
| HyperprolactinaemiaEndocrine disorders | 0/204 | 0/206 | 0/206 | 0/24 | 1/25 | 0/60 | 0/9 | 0/9 | 0/16 | 0/34 | 0/36 | 0/14 |
| Gastric ulcer perforationGastrointestinal disorders | 0/204 | 0/206 | 0/206 | 0/24 | 1/25 | 0/60 | 0/9 | 0/9 | 0/16 | 0/34 | 0/36 | 0/14 |
| Pituitary tumour benignNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/204 | 0/206 | 0/206 | 0/24 | 1/25 | 0/60 | 0/9 | 0/9 | 0/16 | 0/34 | 0/36 | 0/14 |
| Nasal cystRespiratory, thoracic and mediastinal disorders | 0/204 | 0/206 | 0/206 | 0/24 | 1/25 | 0/60 | 0/9 | 0/9 | 0/16 | 0/34 | 0/36 | 0/14 |
| Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/204 | 0/206 | 0/206 | 0/24 | 0/25 | 0/60 | 0/9 | 0/9 | 0/16 | 0/34 | 1/36 | 0/14 |
| Blood uric acid increasedInvestigations | 0/204 | 0/206 | 1/206 | 0/24 | 0/25 | 1/60 | 0/9 | 0/9 | 0/16 | 0/34 | 0/36 | 0/14 |
| Injection site necrosisGeneral disorders | 0/204 | 0/206 | 0/206 | 0/24 | 0/25 | 1/60 | 0/9 | 0/9 | 0/16 | 0/34 | 0/36 | 0/14 |
| ErysipelasInfections and infestations | 0/204 | 0/206 | 0/206 | 0/24 | 0/25 | 1/60 | 0/9 | 0/9 | 0/16 | 0/34 | 0/36 | 0/14 |
| Event | Cladribine 5.25 mg/kg (ITP) | Cladribine 3.5 mg/kg (ITP) | Placebo (ITP) | Cladribine 5.25 mg/kg, Rebif (OLMP) | Cladribine 3.5 mg/kg, Rebif (OLMP) | Placebo, Rebif (OLMP) | Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU) | Cladribine 5.25 mg/kg, Rebif (LTFU) | Cladribine 3.5 mg/kg, Rebif (LTFU) | Placebo, Rebif (LTFU) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PharyngitisInfections and infestations | 12/204 | 10/206 | 12/206 | 2/24 | 9/25 | 3/60 | 0/9 | 0/9 | 0/16 | 0/34 | 0/36 | 0/14 |
| Influenza like illnessGeneral disorders | 0/204 | 0/206 | 0/206 | 7/24 | 9/25 | 21/60 | 0/9 | 0/9 | 0/16 | 0/34 | 0/36 | 0/14 |
| HeadacheNervous system disorders | 58/204 | 64/206 | 57/206 | 5/24 | 8/25 | 10/60 | 1/9 | 0/9 | 3/16 | 2/34 | 0/36 | 0/14 |
| LymphopeniaBlood and lymphatic system disorders | 47/204 | 25/206 | 0/206 | 2/24 | 1/25 | 2/60 | 0/9 | 1/9 | 0/16 | 0/34 | 0/36 | 0/14 |
| PyrexiaGeneral disorders | 0/204 | 0/206 | 0/206 | 1/24 | 5/25 | 5/60 | 0/9 | 0/9 | 0/16 | 0/34 | 0/36 | 0/14 |
| NasopharyngitisInfections and infestations | 36/204 | 35/206 | 38/206 | 2/24 | 1/25 | 5/60 | 0/9 | 1/9 | 0/16 | 0/34 | 0/36 | 0/14 |
| FatigueGeneral disorders | 15/204 | 15/206 | 19/206 | 3/24 | 0/25 | 1/60 | 0/9 | 0/9 | 0/16 | 0/34 | 0/36 | 0/14 |
| Upper respiratory tract infectionInfections and infestations | 23/204 | 21/206 | 17/206 | 0/24 | 0/25 | 0/60 | 1/9 | 0/9 | 2/16 | 0/34 | 0/36 | 0/14 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/204 | 0/206 | 0/206 | 3/24 | 0/25 | 7/60 | 0/9 | 0/9 | 0/16 | 0/34 | 0/36 | 0/14 |
| NauseaGastrointestinal disorders | 23/204 | 24/206 | 19/206 | 1/24 | 1/25 | 3/60 | 0/9 | 0/9 | 0/16 | 0/34 | 0/36 | 0/14 |
The intent-to-treat (ITT) population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo).
| Age, Continuous(years) | Cladribine 5.25 mg/kg | Cladribine 3.5 mg/kg | Placebo | Total |
|---|---|---|---|---|
| Mean | 31.9 ± 8.8 | 31.7 ± 9.2 | 32.2 ± 8.2 | 31.9 ± 8.7 |
| Age, Customized(Participants) | Cladribine 5.25 mg/kg | Cladribine 3.5 mg/kg | Placebo | Total |
|---|---|---|---|---|
| Greater than or equal to 30 years | 111 | 110 | 113 | 334 |
| Less than 30 years | 93 | 96 | 93 | 282 |
| Sex: Female, Male(Participants) | Cladribine 5.25 mg/kg | Cladribine 3.5 mg/kg | Placebo | Total |
|---|---|---|---|---|
| Female | 132 | 130 | 138 | 400 |
| Male | 72 | 76 | 68 | 216 |
| Expanded disability status scale (EDSS) score(units on scale) | Cladribine 5.25 mg/kg | Cladribine 3.5 mg/kg | Placebo | Total |
|---|---|---|---|---|
| Mean | 1.6 ± 0.9 | 1.6 ± 0.9 | 1.7 ± 0.9 | 1.6 ± 0.9 |
| Number of Time Constant 1 (T1) Gadolinium Enhanced (GD+) lesions(lesions) | Cladribine 5.25 mg/kg | Cladribine 3.5 mg/kg | Placebo | Total |
|---|---|---|---|---|
| Mean | 1.9 ± 5.8 | 1.5 ± 4.5 | 0.9 ± 2.5 | 1.4 ± 4.5 |
| Number of T2 Lesions(lesions) | Cladribine 5.25 mg/kg | Cladribine 3.5 mg/kg | Placebo | Total |
|---|---|---|---|---|
| Mean | 29.7 ± 29.6 | 26.8 ± 28.3 | 26.3 ± 27.4 | 27.6 ± 28.4 |
| Time from First Demyelinating Event to Randomization(Days) | Cladribine 5.25 mg/kg | Cladribine 3.5 mg/kg | Placebo | Total |
|---|---|---|---|---|
| Mean | 79.35 ± 17.61 | 78.67 ± 15.97 | 79.40 ± 17.94 | 79.14 ± 17.17 |
| Monofocal/Multifocal Classification (By Adjudication Committee)(Participants) | Cladribine 5.25 mg/kg | Cladribine 3.5 mg/kg | Placebo | Total |
|---|---|---|---|---|
| Monofocal | 108 | 112 | 101 | 321 |
| Multifocal | 96 | 94 | 105 | 295 |
2 further baseline measures are reported on the registry.
Showing the first 100 of 158 sites across 34 countries. Choose a country and city above to see the rest.
Ran from Dec 2008 to primary completion in Jul 2011, 31 months.
Results were first posted in Oct 2013, 2 years 2 months after primary completion.
Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 31 months is below that.
Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cladribine
EMD Serono Research & Development Institute, Inc. →